-
21.发明公开알파-일레오스테아르산을 포함하는 유방암 치료용 조성물및 이를 이용한 피피에이알γ 활성 조절에 의한 질환의치료방법 无效用于治疗包含ALPHA-ELEOSTEACIC酸的乳腺癌的组合物和通过使用其调节PPARγ活性来治疗疾病的方法
公开(公告)号：KR1020090012520A
公开(公告)日：2009-02-04
申请号：KR1020070076422
申请日：2007-07-30
Applicant: 재단법인서울대학교산학협력재단 , 주식회사 리포젠
Abstract: A composition for treatment of breast cancer is provided to investigate anti-cancer capability and mechanism in MCF-7 breast cancer cell using alpha-eleostearic acid. A composition for treatment of breast cancer includes alpha-eleostearic acid to active ingredient. A remedial method of disease at cancer cell line includes a step of processing the alpha-eleostearic acid of a therapeutically effective amount to the cancer cell line and prevents, suppresses or improves pathology or symptom of diseases by adjustment of PPAR gamma activity or phosphorylation of ERK1/2.
Abstract translation: 提供了一种用于治疗乳腺癌的组合物，用于研究使用α-蒿酸的MCF-7乳腺癌细胞的抗癌能力和机制。 用于治疗乳腺癌的组合物包括对活性成分的α-蒿酸。 在癌细胞系疾病的补救方法包括将治疗有效量的α-蒿酸处理至癌细胞系的步骤，通过调整PPARγ活性或ERK1磷酸化来预防，抑制或改善疾病的病理学或症状 / 2。
-
Patent Agency Ranking22.发明授权폴리카프로락톤 다이아크릴레이트와 폴리에틸렌이민을기초로 한 생분해성 폴리에스텔아민을 이용한 새로운유전자 전달체 失效一种基于聚己内酯二丙烯酸酯和聚乙烯亚胺作为基因载体的新型可生物降解聚酯胺
公开(公告)号：KR100860416B1
公开(公告)日：2008-09-26
申请号：KR1020060088277
申请日：2006-09-12
Applicant: 재단법인서울대학교산학협력재단
Abstract: 본 발명은 폴리카프로락톤 다이아크릴레이트와 폴리에틸렌이민을 기초로 한 생분해성 폴리에스텔아민으로 구성된 유전자 전달체에 관한 것이다. 더욱 상세하게는 본 발명은 폴리카프로락톤 다이아크릴레이트와 폴리에틸렌이민을 기초로 한 생분해성 폴리에스텔아민으로 구성된 유전자전달체로써 낮은 세포독성, 생분해성 및 높은 유전자 전달효율로 유전자를 효율적으로 전달하는 뛰어난 효과가 있다.
유전자전달체, 생분해성, 폴리에스텔아민, 폴리카프로락톤 다이아크릴레이트, 폴리에틸렌이민-
23.发明公开경구 파지 디스플레이 방법 및 이로부터 동정된 소장상피세포 흡수촉진 유도 펩타이드, 및 이를 이용한경구투약 시스템 有权使用相同的方法鉴定了该药物和药物递送系统的药物显示过程，ENTEROCYTE-TRANSCYTOTIC PEPTIDEE
公开(公告)号：KR1020070113871A
公开(公告)日：2007-11-29
申请号：KR1020060047714
申请日：2006-05-26
Applicant: 재단법인서울대학교산학협력재단
Abstract: A method for displaying a peroral phage is provided to identify a peptide showing an optimum absorption efficiency passing through small intestine mucosa at highest frequency. And a peroral administration system in which the identified peptide is introduced is provided to increase the absorption efficiency of a protein drug into a bio-membrane significantly, thereby enlarging the usability of the protein drug. A method for displaying a peroral phage comprises the steps of: (a) forming a phage-peptide library; (b) perorally injecting the library into a rat; (c) blood-irrigating the rat; (d) after taking organs from the rat and taking a tissue sample therefrom, washing and homogenizing the sample, neutralizing it and then titrating it; (e) quantifying phage from the sample; and (f) after titrating the separated phage to separate phage DNA therefrom, analyzing a sequence of the DNA to identify a peptide functional group and is characterized in that the steps (b) to (e) are repeated more than 3 times to perform a biopanning, the phage passing through small intestine mucosa after the biopanning is identified at various tissues and organs such as liver, lung, heat, spleen and blood, and an acid elution step after the homogenization step(d) is added to identify an organ targeting peptide specifically bound to a specific tissue after passing through the small intestine mucosa. A peptide identified by the method and inducing the absorption promotion of small intestinal epithelium includes an amino acid sequence of CSKSSDYQC. A peroral administration system is characterized in that the peptide inducing the absorption promotion of small intestinal epithelium is introduced into a protein-based drug.
Abstract translation: 提供了显示口腔噬菌体的方法，以鉴定以最高频率显示通过小肠粘膜的最佳吸收效率的肽。 并且提供其中引入鉴定的肽的口服给药系统，以显着增加蛋白质药物对生物膜的吸收效率，从而增加蛋白质药物的可用性。 用于显示口腔噬菌体的方法包括以下步骤：（a）形成噬菌体肽文库; （b）向图书馆口头注射大鼠; （c）对大鼠进行血液灌洗; （d）从大鼠取出器官并从其中取出组织样品后，洗涤并均匀样品，中和，然后滴定; （e）从样品中量化噬菌体; 和（f）滴定分离的噬菌体以分离噬菌体DNA后，分析DNA的序列以鉴定肽官能团，其特征在于重复步骤（b）至（e）3次以进行 在生物淘选之后，在各种组织和器官如肝，肺，热，脾和血液上鉴定生物淘选后通过小肠粘膜的噬菌体，并且在均匀化步骤（d）之后加入酸洗脱步骤以鉴定器官靶向 通过小肠粘膜后特异性结合于特定组织的肽。 通过该方法鉴定并诱导小肠上皮吸收促进的肽包括CSKSSDYQC的氨基酸序列。 口服给药系统的特征在于将诱导小肠上皮吸收促进的肽引入蛋白质类药物中。
-
公开(公告)号：KR1020060039815A
公开(公告)日：2006-05-09
申请号：KR1020040089046
申请日：2004-11-03
Applicant: 재단법인서울대학교산학협력재단
CPC classification number: C07K14/61 , C07K2319/30 , C12N15/746 , C12N15/815
Abstract: 본 발명은 신규한 경구투여용 재조합 인간 성장호르몬 분비 미생물제제 및 그 제조방법에 관한 것으로, 경구투여를 통해 장내에 안전하게 전달되어 인간 성장호르몬과 IgG1의 Fc 프래그먼트가 결합되어 있는 융합 단백질을 발현할 수 있는 유산균 또는 효모의 미생물제제를 제공하는 뛰어난 효과가 있다. 또한, 본 발명은 장상피세포에서 트랜스사이토시스를 유발할 수 있는 융합 단백질을 발현하는 발현 벡터를 제공하는 뛰어난 효과가 있다. 따라서, 본 발명은 경구투여용 단백질이 장내에서 흡수 가능함을 증명하고, 또한 유산균을 이용한 경구투여용 단백질의 전달방법은 흰쥐 실험을 통해 매우 우수한 효율이 있음을 보여줌으로써 단백질계 약물의 전달체로서 유산균의 우수성을 입증한바, 이로 인해 경제적인 측면이나 이용의 편리성 측면에서 상당한 기여를 할 것으로 기대되므로 의약학산업을 비롯하여 미생물 산업상 매우 유용한 발명이다.
성장호르몬, 면역글로불린, 유산균, 트랜스사이토시스, 효모-
25.发明授权서머스(Ｔｈｅｒｍｕｓ ｓｐ.) ＩＢ-21 유래 신규의내열성 베타-갈락토시다제, ｔｉｂ β-ｇａｌ 失效서머스（Thermus sp。）IB-21래래규규의베갈갈갈갈t t t t t t t t t tβββββββββ
公开(公告)号：KR100465134B1
公开(公告)日：2005-01-13
申请号：KR1020020026802
申请日：2002-05-15
Applicant: 재단법인서울대학교산학협력재단
IPC: C12N15/56
Abstract: PURPOSE: Novel thermostable beta-glycosidase tib β-gal derived from Thermus sp. IB-21 is provided. The enzyme is easily purified because the protein derived from the mesophilic host cell can be easily removed by the simple heat treatment. CONSTITUTION: Novel thermostable beta-glycosidase tib β-gal derived from Thermus sp. IB-21 has the amino acid sequence of SEQ ID NO: 12, wherein the thermostable beta-glycosidase tib β-gal can maintain its activity at pH 7.0 and 70 deg. C for 70 hours or more, and has maximum enzyme activity at pH 5.0 to 6.0 and 80 to 90 deg. C. A gene encoding the amino acid sequence of SEQ ID NO: 12 has the nucleotide sequence of SEQ ID NO: 11. The thermostable beta-glycosidase tib β-gal is combined together in the form of homo-dimer.
Abstract translation: 用途：新型热稳定β-糖苷酶tib＆amp;β-gal来自Thermus sp。 提供IB-21。 该酶易于纯化，因为来自嗜温宿主细胞的蛋白质可以通过简单的热处理容易地除去。 构成：来自Thermus sp。的新型热稳定的β-糖苷酶tib＆amp;β; -gal。 IB-21具有SEQ ID NO：12的氨基酸序列，其中热稳定的β-糖苷酶tib＆amp;β-gal可以在pH7.0和70℃保持其活性。 70小时或更长时间，并且在pH 5.0至6.0和80至90℃下具有最大的酶活性。 编码SEQ ID NO：12的氨基酸序列的基因具有SEQ ID NO：11的核苷酸序列。热稳定的β-糖苷酶tib＆amp;β-gal以同二聚体的形式结合在一起。
-
26.发明授权서머스 필리포미스(Ｔｈｅｒｍｕｓ ｆｉｌｉｆｏｒｍｉｓ)Ｗａｉ 33 Ａ１ 유래 신규의 내열성 베타-글리코시다제,ｔｆｉ β-ｇｌｙ 有权머포포포Therm Therm Therm Therm Therm Therm Therm Therm 33 33 33 33 33 Therm Therm Therm Therm Therm Therm Therm Therm Therm Therm Therm Therm Therm Therm Therm Therm Therm Therm Therm Therm Therm Therm Therm Therm Therm Therm Therm Therm Therm Therm Therm Therm
公开(公告)号：KR100465133B1
公开(公告)日：2005-01-13
申请号：KR1020020026801
申请日：2002-05-15
Applicant: 재단법인서울대학교산학협력재단
IPC: C12N15/56
Abstract: PURPOSE: Thermostable beta-glycosidase tfi β-gly derived from Thermus filiformis Wai 33 A1 is provided. The enzyme is easily purified by the simple heat treatment, maintains its activity at pH 7.0 and 70 deg. C for 70 hours or more, and shows maximum enzyme activity at pH 5.0-6.0 and 80 to 90 deg. C. CONSTITUTION: A thermostable beta-glycosidase tfi β-gly derived from Thermus filiformis Wai 33 A1 has the amino acid sequence of SEQ ID NO: 6, wherein the thermostable beta-glycosidase tfi β-gly has improved lactose degrading activity; and the thermostable beta-glycosidase tfi β-gly is expressed from the recombinant Escherichia coli containing a gene encoding the thermostable beta-glycosidase tfi β-gly. The gene encoding the amino acid sequence of SEQ ID NO: 6 has the nucleotide sequence of SEQ ID NO: 5.
Abstract translation: 目的：提供来自Thermus filiformis Wai 33 A1的热稳定的β-糖苷酶tfi＆amp;β-gly。 该酶易于通过简单的热处理纯化，在pH 7.0和70℃下保持其活性。 70小时或更长时间，并且在pH 5.0-6.0和80-90℃显示最大的酶活性。 C.构成：来源于丝状栖热菌属（Thermus filiformis）外33A1的热稳定的β-糖苷酶tfi＆amp;β-gly具有SEQ ID NO：6的氨基酸序列，其中热稳定的β-糖苷酶tfiβ- 乳糖降解活性; 并且从含有编码热稳定的β-糖苷酶tfiβ-gly的基因的重组大肠杆菌中表达热稳定的β-糖苷酶tfiβ-gly。 编码SEQ ID NO：6的氨基酸序列的基因具有SEQ ID NO：5的核苷酸序列。
-
-
-
-
-
Search Results
26
records
(took 0.035 seconds)
